Publications

Flume PA, Nordyke RJ, Han D, Jha A, Nicholson G, Peipert JD. 2026. Patient-reported outcome measures developed for non-cystic fibrosis bronchiectasis may be applied to cystic fibrosis bronchiectasis. Health Qual Life Outcomes; doi: 10.1186/s12955-026-02546-4. Online ahead of print May 13. PMID: 42129785.

Nordyke RJ. Panel Moderator: Can new approaches to estimating dynamic efficiency help to maintain both access and innovation in pharmaceutical markets? ISPOR 2026, Philadelphia, PA, May 19, 2026.

Nordyke RJ, Cyr P, Jensen I. Gene therapy development programs are both growing and evolving in the face of commercial headwinds. Poster Session 3/No. HPR71, ISPOR 2026, Philadelphia, PA, May 19, 2026.

Nordyke RJ, Jensen I, Hooda N, Miller B. Rising levels of innovation in expedited designations among FDA-approved drugs: 2012-2024. Poster Session 2/No. HPR63, ISPOR 2026, Philadelphia, PA, May 18, 2026.

Nordyke RJ, Patterson JA, Motyka J, March B, Kirson NY, Long G. 2025. The impact of the Inflation Reduction Act’s drug price negotiation program on incentives for clinical development of new drugs. Value Health 28(12)1881-1889; doi: 10.1016/j.jval.2025.08.011. PMID: 40902797.

Nordyke RJ, Motyka J, Patterson JA. 2025. The association of 340B program drug margins with covered entity characteristics. Inquiry 62(Jan-Dec):469580251324051; doi: 10.1177/00469580251234051. PMID: 4012322.

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002. PMID: 39357669.

Patterson JA, Motyka J, Salih R, Nordyke RJ, O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6. PMID: 39369117.

Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ, Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2. PMID: 38170435.

Wagner TD, Westrich KD, Nordyke RJ, Campbell JD. 2024. Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: Contextualizing drug spending changes. J Med Econ 27(1):1537-1541; doi: 10.1080/13696998.2024.2428109. PMID: 39626873.

Woo K, Fuld R, Grandinetti A, Lawson J, Litchfield T, Ohan M, Peipert JD, Rivara MB, Nordyke RJ. 2022. Patient-reported outcomes in hemodialysis vascular access: A call to action. J Vasc Access 23(6):973-980; doi: 10.1177/11297298211018295. PMID: 34032166.

Cooper M, Schnitzler M, Nilubol C, Wang W, Wu Z, Nordyke RJ. 2022. Costs in the year following deceased donor kidney transplantation: Relationships with renal function and graft failure. Transpl Int. 35(May):10422. doi: 10.3389/ti.2022.10422. PMID: 35692736.

Schold JD, Nordyke RJ, Wu Z, Corvino F, Wang W, Mohan S. 2022. Clinical events and renal function in the first year predict long-term kidney transplant survival. Kidney360 3(4):714-727; doi: 10.34067/KID.0007342021. PMID: 35721618.

Mayne TJ, Nordyke RJ, Schold JD, Weir MR, Mohan S. 2021. Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. Clin Transplant 35(7):e14326; doi: 10.1111/ctr.14326. PMID: 33896052.

Halbert RJ, Nordyke RJ, Nicholson G, Pilgrim A, Niklason L. 2020. Patency of ePTFE arteriovenous graft placements in hemodialysis patients: Systematic literature review and meta-analysis. Kidney360 1(12):1437–1446; doi: 10.34067/KID.0003502020. PMID: 35372887.

Flythe JE, Hilliard TS, Ikeler K, Keller S, Gipson DS, Grandinetti AC, Nordyke RJ, Perrone RD, et al. 2020. Toward patient-centered innovation: A conceptual framework for patient-reported outcome measures for transformative kidney replacement devices. Clin J Am Soc Nephrol 15(10):1522-1530; doi: 10.2215/CJN.00110120. PMID: 32276947.

Su J, Bylsma LC, Jiang X, Morales Arias J, Jain N, Nordyke RJ. 2020. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. J Med Econ 23(8):902-907; doi: 10.1080/13696998.2020.1764006. PMID: 32362156.

Busse LW, Nicholson G, Nordyke RJ, Lee C-H, Zeng F, Albertson TE. 2020. Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis. Intl J Tech Assess Health Care 36(2):145-151; doi: 10.1017/S0266462320000082. PMID: 32114996.

Nordyke RJ, Nicholson G, Gage SM, Lithgow T, Himmelfarb J, Rivara MB, Hays RD, Woo K, Peipert JD. 2020. Vascular access-specific health-related quality of life impacts among hemodialysis patients: Qualitative development of the hemodialysis access-related quality of life (HARQ) instrument. BMC Nephrol 14;21(1):16; doi: 10.1186/s12882-020-1683-5. PMID: 31937249.

Nordyke RJ, Appelbaum K, Berman MA.  2019. Estimating the impact of novel digital therapeutics in Type 2 diabetes and hypertension: Health economic analysis. J Med Internet Res 21(10):e15814; doi: 10.2196/15814. PMID: 31937249.